Status:
UNKNOWN
Myfortic in Heart Transplant Patients With Gastrointestinal (GI) Symptoms
Lead Sponsor:
McGill University Health Centre/Research Institute of the McGill University Health Centre
Collaborating Sponsors:
Novartis
Conditions:
Heart Transplant Patients
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Stable heart transplant patients on Mycophenolate Mofetil (MMF) will sign a screening consent form in order to be evaluated with the gastrointestinal symptom rating scale (GSRS) questionnaire. Those w...
Eligibility Criteria
Inclusion
- Stable dose MMF for at least 4 weeks
- Over 18 years of age
- Heart transplant at least three months prior to study
Exclusion
- GI symptoms known not to be caused by MPA therapy
- Acute rejection episode in past 4 weeks
- History of malignancy since transplant
- Pregnancy
Key Trial Info
Start Date :
May 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2009
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00468936
Start Date
May 1 2007
End Date
December 1 2009
Last Update
October 17 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
McGill University Health Centre
Montreal, Quebec, Canada, H3A 1A1